Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Vivos Therapeutics (VVOS) Enterprise Value (2019 - 2025)

Vivos Therapeutics has reported Enterprise Value over the past 7 years, most recently at -$2.1 million for Q4 2025.

  • Quarterly Enterprise Value rose 66.63% to -$2.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.1 million through Dec 2025, up 66.63% year-over-year, with the annual reading at -$2.1 million for FY2025, 66.63% up from the prior year.
  • Enterprise Value was -$2.1 million for Q4 2025 at Vivos Therapeutics, up from -$3.1 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$1.0 million in Q3 2023 and troughed at -$34.2 million in Q2 2021.
  • The 5-year median for Enterprise Value is -$6.3 million (2024), against an average of -$9.5 million.
  • Year-over-year, Enterprise Value soared 85.34% in 2022 and then plummeted 531.1% in 2024.
  • A 5-year view of Enterprise Value shows it stood at -$24.0 million in 2021, then soared by 85.34% to -$3.5 million in 2022, then skyrocketed by 53.31% to -$1.6 million in 2023, then plummeted by 281.01% to -$6.3 million in 2024, then skyrocketed by 66.63% to -$2.1 million in 2025.
  • Per Business Quant, the three most recent readings for VVOS's Enterprise Value are -$2.1 million (Q4 2025), -$3.1 million (Q3 2025), and -$4.4 million (Q2 2025).